Last updated: February 19, 2026
Hydralazine hydrochloride is a vasodilator used primarily to treat hypertension and heart failure. The drug is produced by multiple pharmaceutical manufacturers and supplied through various distributors globally.
Major Manufacturers and Suppliers
| Company |
Headquarters |
Manufacturing Locations |
Certification |
Notable Markets |
| Pfizer |
United States |
United States, Puerto Rico |
FDA approved |
US, EU, APAC |
| Novartis |
Switzerland |
Switzerland, US, India |
EMA approved |
Global |
| Mylan (now part of Viatris) |
US |
US, India |
FDA, EMA |
US, India, Europe |
| Teva Pharmaceutical Industries |
Israel |
Israel, US, India |
FDA, EMA |
US, EU, ROW |
| Aurobindo Pharma |
India |
India, US |
US FDA, EU EMA |
US, EU, ROW |
| Sun Pharma |
India |
India, US |
US FDA |
US, EU |
| Lupin |
India |
India, US |
US FDA |
US, EU |
| Cipla |
India |
India, US |
US FDA |
US, EU, ROW |
Distribution Channels
- Pharmaceutical Distributors: Major distributors like McKesson, Cardinal Health, and Almac supply hydralazine hydrochloride in bulk to hospitals and pharmacies.
- Generic Drug Suppliers: Numerous Indian and Chinese generic manufacturers supply the drug to international markets, often at lower prices.
- OEM Partners: Some companies produce hydralazine hydrochloride under contract manufacturing arrangements for brand and generic companies.
Regulatory Certifications and Standards
- Most approved suppliers hold certifications like the US FDA approval, European EMA certification, or WHO prequalification.
- Batch production follows Good Manufacturing Practice (GMP) guidelines, ensuring product consistency and quality.
- Suppliers must comply with pharmacopoeial standards (USP, BP, EP) for API quality.
Geographic Supply Variations
| Region |
Key Suppliers |
Market Shares |
Import Regulations |
| North America |
Pfizer, Mylan, Teva |
~50% |
Stringent FDA regulation |
| Europe |
Novartis, Teva, Lupin |
~40% |
EMA approval required |
| Asia-Pacific |
Aurobindo, Sun Pharma, Cipla |
~70% |
Local registration required |
| Africa & Middle East |
Local distributors, Indian suppliers |
Variable |
Import licensing required |
Market Trends and Considerations
- Production of hydralazine hydrochloride has shifted increasingly towards India and China, owing to lower manufacturing costs.
- Supply chain disruptions caused by global events, such as the COVID-19 pandemic, have impacted availability.
- The increased demand for affordable generic formulations has expanded the supplier base but also heightened quality control demands.
Sources
[1] U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] European Medicines Agency (EMA). (2022). List of medicines approved in the EU.
[3] IQVIA. (2022). World Pharmaceutical Market Analysis.
[4] GlobalData. (2022). Global API and Finished Dosage Supply Chain Report.
[5] Indian Pharma News. (2022). API manufacturing trends in India.
Key Takeaways
- Major global suppliers include Pfizer, Novartis, Mylan, Teva, and Indian manufacturers like Aurobindo, Sun Pharma, and Lupin.
- Supply is concentrated in North America, Europe, and India, with India and China increasing their market share in API production.
- Suppliers comply with strict regulatory standards, including FDA, EMA, and GMP practices.
- Supply dynamics are influenced by regional regulations, manufacturing costs, and global supply chain disruptions.
- Pharmaceutical-grade hydralazine hydrochloride requires adherence to pharmacopoeial standards, with certifications serving as quality indicators.
FAQs
1. Which companies dominate the hydralazine hydrochloride supply market?
Pfizer, Novartis, and Indian generic manufacturers like Aurobindo and Sun Pharma.
2. What certifications should buyers verify before sourcing?
FDA approval, EMA certification, GMP compliance, and pharmacopoeial standards (USP, BP, or EP).
3. Are there regional differences in supplier quality?
Yes. Suppliers in North America and Europe generally meet stricter standards compared to some manufacturers in developing countries, although many Indian and Chinese producers maintain rigorous quality controls.
4. How has COVID-19 affected the supply of hydralazine hydrochloride?
Disruptions have caused delays and shortages, prompting increased reliance on Indian and Chinese suppliers.
5. What are key considerations for sourcing hydralazine hydrochloride internationally?
Regulatory compliance, certification standards, supply chain stability, and cost-effectiveness.
Sources
- U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
- European Medicines Agency (EMA). (2022). List of medicines approved in the EU.
- IQVIA. (2022). World Pharmaceutical Market Analysis.
- GlobalData. (2022). Global API and Finished Dosage Supply Chain Report.
- Indian Pharma News. (2022). API manufacturing trends in India.
